Site icon Duncan Bucknell

Pharma & Biotech Global Week in Review 2 June 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page:

Highlights this week included:

US: Sen Kerry introduces Angiomax PTE amendment to Tax Extenders Act of 2009 (FDA Law Blog)


Nature Biotechnology and more anti-gene patenting myths (Patent Docs)

Alice de Pastor’s SPC news 2009 (The SPC Blog)

US: Sen Kerry introduces Angiomax PTE amendment to Tax Extenders Act of 2009 (FDA Law Blog)

US: Blinded by science: Myriad loses breast cancer test patents (Patent Baristas)

US: Cornell University, others file patent infringement suit against Illumina over its GoldenGate Genotyping Assay and DASL Assay and services using those assays (Patent Docs)

US: Biotech/Pharma issuances on the rise (Patent Docs)


Actos (Piotglitazone) – US: Takeda files patent infringement complaint against Dr Reddy’s following Para IV certification (Patent Docs)

Cipro (Ciprofloxacin) – US: Pharma pay-for-delay ok? – In re Ciprofloxacin Antitrust Litigation (PatLit)

Circumvent PCV and Porcilis PCV vaccines – US: Wyeth files patent infringement suit against Intervet based on their manufacture of PCV vaccines (Patent Docs)

Copegus (Ribavirin) – US: Ascio seeks declaratory judgment of unenforceability, invalidity and non-infringement of Three Rivers’ patent based on ANDA filing (Patent Docs)

Entocort (Budesonide) – US: AstraZeneca settles Entocort patent suit with Teva, stipulates with Mylan (Patent Docs)

Hectorol (Doxercalciferol) – US: Genzyme files patent infringement complaint against Sandoz following ANDA filing: (Patent Docs)

Herceptin (Trastuzumab) – US: Genentech seeks declaratory judgment of non-infringement and patent invalidity: Genentech, Inc v Trustees of the University of Pennsylvania (Patent Docs)

Prilosec (Omeprazole) – US: Mylan’s antitrust claims dismissed in AstraZeneca Prilosec suit (Patent Docs)

Renvela (Sevelamer carbonate) – US: Genzyme files patent infringement complaint against Watson following Para IV challenge (Patent Docs)

Solaraze (Diclofenac) – US: Nycomed seeks declaratory judgment that Tolmar’s Para IV notice was improper (Patent Docs)

Tarceva (Erlotinib) – India: Update on Roche v Natco litigation (Generic Pharmaceuticals and IP) (Spicy IP)

Thalomid (Thalidomide) – US: Celgene announces dismissal of suit against Barr Laboratories following withdrawal of Thalidomide ANDA (SmartBrief)

Uroxatral (Alfuzosin) – US: Sanofi-Aventis’ Uroxatral patent valid, Mylan’s generic infringes (Patent Docs)

Valcyte (Valganciclovir) – India: Roche’s patent rejection: A numerical quantifier for Section 3(d)? (Spicy IP)

Wellbutrin (Bupropion) – US: Pennsylvania District Court decision signals a new turn in the generic drug preemption debate; a tough pill to swallow for the generic industry: In re Budeprion XL Marketing & Sales Litigation (FDA Law Blog)

Exit mobile version